Formycon Reveals Keytruda Biosimilar In The Works

A Formulation Patent Is Pending While Manufacturing Capacity Has Been Secured

Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.

Pembrolizumab molecule
Formycon has revealed pembrolizumab as one of its in-development biosimilars • Source: Shutterstock

Formycon has announced it is conducting advanced pre-clinical development for a Keytruda (pembrolizumab) biosimilar, previously referred to only by its codename FYB206.

Pembrolizumab, a humanized monoclonal antibody, helps the immune system fight tumors by binding to the PD-1 receptor and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products